Altamira Therapeutics Ltd.

OTCPK:CYTO.F Stock Report

Market Cap: US$568.4k

Altamira Therapeutics Management

Management criteria checks 4/4

Altamira Therapeutics' CEO is Thomas Meyer, appointed in Apr 2003, has a tenure of 22.08 years. total yearly compensation is $606.17K, comprised of 52.3% salary and 47.7% bonuses, including company stock and options. directly owns 18.8% of the company’s shares, worth $106.84K. The average tenure of the management team and the board of directors is 2.9 years and 7.6 years respectively.

Key information

Thomas Meyer

Chief executive officer

US$606.2k

Total compensation

CEO salary percentage52.30%
CEO tenure22.1yrs
CEO ownership18.8%
Management average tenure2.9yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID

Sep 13

Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio

Aug 30

Altamira starts development program for potential arthritis therapy

Jul 25

Altamira announces peer-reviewed publication on mRNA delivery platform

Jul 19

Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform

Jul 12

Auris Medical shares rise on OligoPhore Lymphoma study results

Jun 21

Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

Dec 09
Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

CEO Compensation Analysis

How has Thomas Meyer's remuneration changed compared to Altamira Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$606kUS$317k

-US$8m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$779kUS$435k

-US$8m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$18m

Jan 01 2023n/an/a

-US$20m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$401k

-US$7m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$741kUS$411k

-US$9m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$606kUS$376k

-US$7m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$636kUS$370k

-US$12m

Compensation vs Market: Thomas's total compensation ($USD606.17K) is about average for companies of similar size in the US market ($USD645.28K).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.


CEO

Thomas Meyer (56 yo)

22.1yrs
Tenure
US$606,169
Compensation

Dr. Thomas Meyer, Ph.D. Founded Altamira Therapeutics Ltd. (formerly known as Auris Medical Holding Ltd.) (formerly known as Auris Medical Holding AG) in April 2003 and serves as Managing Director, Chairma...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meyer
Founder22.1yrsUS$606.17k18.8%
$ 106.8k
Marcel Gremaud
Chief Financial Officer3.5yrsno data0.00056%
$ 3.2
Covadonga Paneda
Chief Operating Officer2.3yrsno datano data
Samuel Wickline
Chief Scientific Adviser2.3yrsno datano data
2.9yrs
Average Tenure
61yo
Average Age

Experienced Management: CYTO.F's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Meyer
Founder22.1yrsUS$606.17k18.8%
$ 106.8k
Alain Munoz
Independent Non-Executive Director7.2yrsUS$63.23k0.0049%
$ 27.6
Mats Blom
Independent Non-Executive Director8.1yrsUS$63.23k0.0049%
$ 27.7
Dominik Lysek
Independent Director1yrUS$22.50kno data
7.6yrs
Average Tenure
57.5yo
Average Age

Experienced Board: CYTO.F's board of directors are considered experienced (7.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 19:53
End of Day Share Price 2025/05/22 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Altamira Therapeutics Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liisa BaykoCitizens JMP Securities, LLC
Hunter DiamondDiamond Equity Research LLC
Maxim JacobsEdison Investment Research